TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moleculin Biotech ( (MBRX) ) has shared an update.
On October 16, 2025, Moleculin Biotech held a Special Meeting of Stockholders where several proposals were voted on. The stockholders approved the issuance of up to 64,864,864 shares of common stock upon the exercise of certain warrants, but did not approve the proposal to change the company’s name to Moleculin Inc. Additionally, they approved an adjournment to solicit more proxies if needed for the Nasdaq Proposal or the Name Change Proposal.
The most recent analyst rating on (MBRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech operates in the biotechnology industry, focusing on developing treatments for highly resistant cancers and viruses. The company is known for its innovative approach to drug development, particularly in oncology and infectious diseases.
Average Trading Volume: 3,430,541
Technical Sentiment Signal: Sell
Current Market Cap: $25.24M
Learn more about MBRX stock on TipRanks’ Stock Analysis page.